Results 201 to 210 of about 326,099 (315)
Temperature and intrinsic Ca<sup>2+</sup> reshape TRPM4 pharmacology. [PDF]
Hu J +8 more
europepmc +1 more source
A new generation of high‐precision fluorescent probes based on the lysosomal characteristics in tumor metabolic reprogramming and overexpressed tumor markers. The probe (CN‐D‐GGT) selectively label cancer cells in co‐culture systems and distinguish tumor lesions from inflamedand normal tissues in vivo, enabling precise tumor imaging.
Yang Shen +6 more
wiley +1 more source
Genetic Alterations Shaping the Functional Properties of DyP Peroxidases. [PDF]
Saad MM +3 more
europepmc +1 more source
SMarT‐Diff introduces a multi‐objective generative paradigm that integrates scaffold hopping with structure‐aware scoring to enable controlled exploration beyond the training distribution. The framework consistently balances drug‐likeness, synthesizes accessibility and bioactivity, yielding chemically diverse candidates with enhanced properties.
Yuwei Yang +8 more
wiley +1 more source
KNexPHENIX: A PHENIX-Based Workflow for Improving Cryo-EM and Crystallographic Structural Models. [PDF]
Nandi S, Conn GL.
europepmc +1 more source
A sulfated polysaccharide (SCP) from Cyclocarya paliurus alleviates ulcerative colitis by reshaping the gut microbiome. This remodeled microbiota orchestrates the upregulation of the host‐derived lipid 12‐HEPE, which directly inhibits the TLR4/NF‐κB pathway to suppress inflammation.
Xianxiang Chen +11 more
wiley +1 more source
Stage-dependent role of NEK7 in the inactive-to-active conformational transition of NLRP3 monomer. [PDF]
Peng J +5 more
europepmc +1 more source
Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases
There is no drug targeting the NLRP3 inflammasome that has been approved for use in clinical settings. Ciclopirox olamine (CPX), an antifungal agent approved by the US Food and Drug Administration (FDA), is identified as a specific and potent NLRP3 inflammasome inhibitor. CPX targets the NACHT domain of NLRP3 at Y381 to impair NLRP3 oligomerization and
Xinyu Xia +7 more
wiley +1 more source
Structural basis for activation and potentiation in a human α5β3 GABA<sub>A</sub> receptor. [PDF]
Cowgill J +4 more
europepmc +1 more source

